Clinical trial register · Israel

Clinical Trials in Ramat Gan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2426 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:18 UTC

2426

Studies in scope

all four open statuses

1233

Recruiting now

open to new participants

457

Lead sponsors

across recruiting studies

Top sites

Jerusalem 838 Haifa 739 Tel Aviv 695 Ramat Gan 648 Petah Tikva 616

Trials with a site in Ramat Gan

Status

Study

Lead sponsor

Phase

Enrol

Sites in Israel

Start

Not yet open

Stratification and Treatment in Early Psychosis Study -ASSIST

NCT07326124Treatment Resistant Psychosis, Psychosis

University of Oxford

Phase 3

250

Hod HaSharon, Petah Tikva, Ramat Gan

2027-01

Recruiting

A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

NCT07709000Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies

DrugsAvtozma·Tyenne·Siltuximab·MK-1045

Merck Sharp & Dohme LLC

Phase 2

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2026-10-14

Recruiting

Stratification and Treatment in Early Psychosis Study - ENHANCE

NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode

University of Oxford

Phase 3

250

Hod HaSharon, Petah Tikva, Ramat Gan

2026-10-05

Not yet open

LLM-Generated Medical Summaries During Hospitalization to Improve Patient Activation in High-Risk Pregnancies

NCT07823517High-risk Pregnancy, Hospitalization, Patient Activation, Artificial Intelligence (AI)

Sheba Medical Center

Not applicable

200

Ramat Gan

2026-10-01

Not yet open

Combination CurQD and Vedolizumab in Ulcerative Colitis

NCT07665294Ulcerative Colitis

DrugVedolizumab

Ryan C Ungaro

Phase 4

160

Ramat Gan

2026-10-01

Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450Multiple Myeloma

DrugsRamantamig·Bortezomib·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,000

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-09-09

Recruiting

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

NCT07630714Systemic Lupus Erythematosus

AstraZeneca

Phase 2

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2026-08-31

Recruiting

Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Quality of Life of Children and Youth With Type 1 Diabetes

NCT07828106Diabetes Mellitus, Type 1 Diabetes, Mobile Health Platform, Mobile Health Technology (mHealth), Mobile Health

Sheba Medical Center

Not applicable

100

Ramat Gan

2026-08-25

Recruiting

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743Sjögren's Disease

DrugDDY391

Novartis Pharmaceuticals

Phase 2

344

Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2026-08-24

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Ashkelon, Be’er Ya‘aqov, Hadera, Haifa, Holon, Kfar Saba, Nahariya, Ramat Gan

2026-08-21

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma

DrugsTelisotuzumab Adizutecan·Nab-paclitaxel·Gemcitabine

AbbVie

Phase 2

168

Ramat Gan, Jerusalem

2026-08-17

Recruiting

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT07612267Lactation, Inflammatory Bowel Disease

DrugMirikizumab

Eli Lilly and Company

Phase 4

HaMerkaz, Jerusalem, Ramat Gan, Tel Aviv

2026-08-05

Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

NCT07227896Parkinson's Disease

AbbVie

Observational

100

Jerusalem, Ramat Gan, Tel Aviv

2026-08-03

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Haifa, Kfar Saba, Ramat Gan

2026-07-27

Recruiting

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-07-21

Recruiting

Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)

NCT07227805Diabetes (Insulin-requiring, Type 1 or Type 2)

Medtronic MiniMed, Inc.

Not applicable

116

Ramat Gan

2026-07-19

Recruiting

IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel Syndrome

NCT07707635Irritable Bowel Syndrome (IBS)

Ariel University

Not applicable

150

Ramat Gan

2026-07-19

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444Rett Syndrome

DrugFintepla

UCB BIOSCIENCES, Inc.

Phase 3

200

Ramat Gan

2026-07-14

Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07630974Malignant Neoplasm

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

134

Haifa, Petah Tikva, Ramat Gan

2026-07-06

Recruiting

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

NCT07387926Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

DrugsABL001·Hydrocortisone·Blinatumomab·Prednisolone

Novartis Pharmaceuticals

Phase 1/2

Ramat Gan

2026-07-05

Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

Ramat Gan, Jerusalem

2026-07-02

Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938Multiple Myeloma

DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide

Hoffmann-La Roche

Phase 3

380

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2026-06-23

Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471Follicular Lymphoma

DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2/3

960

Jerusalem, Ramat Gan, Tel Aviv

2026-06-22

Not yet open

A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

NCT07503353B Cell Malignancies, Acute Lymphobkastic Leukemia, Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)

Sheba Medical Center

Phase 1/2

Ramat Gan

2026-06

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Ashdod, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-31

Recruiting

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879Colitis, Ulcerative

DrugEtrasimod

Pfizer

Phase 2

Ramat Gan, Rehovot, Tsrifin, Jerusalem, Haifa

2026-05-28

Recruiting

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

NCT07609914Acute Treatment of Migraine

DrugRimegepant

Pfizer

Phase 4

400

Ramat Gan, Jerusalem, Tel Aviv

2026-05-28

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856Colitis, Ulcerative

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

644

Ashdod, Haifa, Holon/Tel Aviv, Kefar Sava, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-23

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843Crohn Disease

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

460

Ashdod, Haifa, Holon/Tel Aviv, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-21

Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173B-cell Acute Lymphoblastic Leukemia

DrugsAvtozma·Tyenne·Siltuximab·MK-1045

Merck Sharp & Dohme LLC

Phase 2/3

340

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2026-05-18

Recruiting

A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

NCT06087536Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia

Omnix Medical Ltd

Phase 2

Ashdod, Be’er Ya‘aqov, Holon, Petah Tikva, Ramat Gan, Rishon LeZiyyon

2026-05-14

Recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma

DrugsPF-08634404·Nivolumab

Pfizer

Phase 2/3

840

Petah Tikva, Ramat Gan, Tel Aviv

2026-05-14

Active, closed

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan

2026-05-11

Recruiting

Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage

NCT07401524Postpartum Hemorrhage, Twin Pregnancy

DrugsCarbetocin·Oxytocin

Sheba Medical Center

Phase 4

120

Ramat Gan

2026-05-05

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsDeutenzalutamide·Xofigo·FPI-2265·Cabazitaxel

AstraZeneca

Phase 3

670

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-04

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2026-05-04

Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin

2026-05-04

Recruiting

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073Colitis, Ulcerative, Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin

2026-05-04

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

DrugMK-1045

Merck Sharp & Dohme LLC

Phase 1/2

280

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2026-05-03

Recruiting

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma, PDAC

DrugsTelisotuzumab Adizutecan·Fluorouracil·Irinotecan·Oxaliplatin

AbbVie

Phase 2/3

900

Ramat Gan, Tel Aviv, Haifa, Jerusalem

2026-04-30

Recruiting

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

NCT07286149Lung Neoplasm Malignant

DrugsCalderasib·Patritumab deruxtecan·Erbitux·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

140

Jerusalem, Kfar Saba, Ramat Gan

2026-04-30

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

360

Ramat Gan

2026-04-27

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin

2026-04-23

Recruiting

Arm Position and Blood Pressure Measurement Accuracy During Pregnancy

NCT07405723Pregnancy, Blood Pressure Measurement in Pregnancy, Hypertensive Disorder of Pregnancy

Sheba Medical Center

Not applicable

300

Ramat Gan

2026-04-12

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Haifa, Kfar Saba, Petah Tikva, Ramat Gan

2026-04-09

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

DrugsTiespectus·Eylea·Aflibercept

EyeBiotech Ltd.

Phase 2/3

960

Ashkelon, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tsrifin

2026-03-27

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-03-23

Recruiting

Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT07360080Type 1 Diabetes

DrugTeplizumab

Sanofi

Observational

1,000

Petah Tikva, Ramat Gan

2026-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470Kidney Transplant Rejection

DrugsRabbit anti-thymocyte globulin·Frexalimab·Mycophenolate Mofetil·Tacrolimus

Sanofi

Phase 2/3

526

Ramat Gan

2026-03-13

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)

DrugEnpatoran

EMD Serono Research & Development Institute, Inc.

Phase 3

202

Ramat Gan

2026-03-10

Recruiting

Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder - a Pragmatic, Double Blinded Randomized Trial

NCT07473362PTSD - Post Traumatic Stress Disorder

Medical Corps, Israel Defense Force

Not applicable

Ramat Gan

2026-03-01

Recruiting

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246Multiple Myeloma

AbbVie

Phase 1

127

Ramat Gan, Tel Aviv, Jerusalem

2026-02-27

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Haifa, Holon, Ramat Gan

2026-02-16

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2026-02-05

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Beersheba, Haifa, Jerusalem, Ramat Gan, Ramat Poriya, Tel Aviv

2026-02-04

Recruiting

Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

NCT07919015Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis

DrugNerandomilast

Avraham Unterman

Observational

Ashkelon, Haifa, Ramat Gan, Tel Aviv

2026-02-01

Recruiting

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

NCT07226089ISS, SGA

DrugSomatrogon

Rabin Medical Center

Phase 3

254

Petah Tikva, Jerusalem, Bear Sheva, Ramat Gan, Rishon LeZiyyon, Tel Aviv

2026-02-01

Recruiting

A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

NCT07135466B Cell Malignancies

Sheba Medical Center

Phase 1/2

Ramat Gan

2026-02-01

Not yet open

Mitochondrial Function After Ketamine

NCT07399756Major Depressive Disorder

DrugKetamine

Sheba Medical Center

Observational

Ramat Gan

2026-02

Recruiting

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

NCT07227597Small Cell Lung Cancer Extensive Stage

DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab

Merck Sharp & Dohme LLC

Phase 1/2

170

Haifa, Ramat Gan

2026-01-29

By invitation

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07286006Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

372

Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-01-26

Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190Uveal Melanoma

DrugDarovasertib

IDEAYA Biosciences

Phase 3

520

Ramat Gan, Jerusalem

2026-01-25

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Haifa, Jerusalem, Kfar Saba, Ramat Gan, Tel Aviv

2026-01-16

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2026-01-12

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07284459Idiopathic Pulmonary Fibrosis

Contineum Therapeutics

Phase 2

324

Be’er Ya‘aqov, Kafr Saba, Petah Tikva, Ramat Gan, Rehovot, Hadera, Jerusalem, Ashdod

2026-01-08

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Tel Aviv

2026-01-06

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Kfar Saba, Ramat Gan, Jerusalem, Afula, Haifa

2026-01-02

Recruiting

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

NCT07265947Low Grade Upper Tract Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

285

Holon, Ramat Gan, Tel Aviv, Jerusalem, Kfar Saba

2025-12-22

Recruiting

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT07247110Malignant Neoplasm

DrugsCetuximab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

250

Haifa, Petah Tikva, Ramat Gan

2025-12-16

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Petah Tikva, Ramat Gan, Haifa, Jerusalem, Tel Aviv

2025-12-11

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Kefar Sava, Petah Tikva, Tsrifin, Ramat Gan, Haifa

2025-12-10

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Petah Tikva, Ramat Gan, Tel Aviv

2025-12-03

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

Haifa, Beersheba, Petah Tikva, Jerusalem, Tel Aviv, Kfar Saba, Ramat Gan

2025-12-03

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Petch Tikva, Netanya, Ramat Gan, Rishon Le'Tzion

2025-12-02

Recruiting

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031Chronic Graft Versus Host Disease

DrugBelumosudil

Sanofi

Phase 2

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-12-02

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644Solid Tumors Harboring MET Amplification

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

100

Petah Tikva, Ramat Gan, Tel Aviv, Jerusalem

2025-12-01

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336Ovarian Cancer

DrugsBevacizumab·Carboplatin

AbbVie

Phase 1

285

Ramat Gan, Haifa, Jerusalem

2025-11-27

Recruiting

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174Small Cell Lung Cancer

DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab

AbbVie

Phase 2

180

Kefar Sava, Ashdod, Ramat Gan, Haifa, Jerusalem

2025-11-25

Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

NCT07241039Advanced Squamous Tumors

DrugBudigalimab

AbbVie

Phase 1

220

Ramat Gan, Haifa, Jerusalem

2025-11-20

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Ashkelon, Hadera, Haifa, Jerusalem, Ramat Gan, Rehovot, Tel Aviv, Tsrifin

2025-11-11

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Ashkelon, Haifa, Jerusalem, Ramat Gan, Tel Aviv

2025-11-06

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225Non-muscle Invasive Bladder Cancer

DrugSasanlimab

Pfizer

Phase 1

294

Petah Tikva, Ramat Gan, Jerusalem, Haifa

2025-11-06

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Holon, Petah Tikva, Rehovot, Tsrifin, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2025-11-05

Recruiting

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

NCT07293923Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)

Magenta Medical Ltd.

Not applicable

Be’er Ya‘aqov, Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-11-05

Recruiting

Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure

NCT07881666Urinary Bladder Neoplasms

Hopec Pharma

Phase 1

Kfar Saba, Jerusalem, Ramat Gan

2025-10-25

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Ramat Gan, Tsrifin, Jerusalem, Afula, Tel Aviv, Petah Tikva

2025-10-23

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Ramat Gan, Tel Aviv

2025-10-20

Recruiting

Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery

NCT07224451Spinal Tumors

Sheba Medical Center

Not applicable

Ramat Gan

2025-10-16

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-10-15

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Platinol-AQ·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

675

Beer Ya Akov, Jerusalem, Kfar Saba, Ramat Gan, Tel Aviv

2025-10-08

Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913Mania, Bipolar Disorder

DrugKarXT

Bristol-Myers Squibb

Phase 3

424

Hod HaSharon, Ramat Gan, Ashkelon, Beersheba, Jerusalem

2025-10-08

Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285Systemic Lupus Erythematosus (SLE)

Bristol-Myers Squibb

Observational

223

Kfar Saba, Ramat Gan, Haifa, Petah Tikva, Tel Aviv

2025-10-08

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Petah Tikva, Ramat Gan, Haifa, Jerusalem, Tel Aviv

2025-10-03

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan

2025-10-03

Recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Petah Tikva, Ramat Gan

2025-10-01

Recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Petah Tikva, Ramat Gan

2025-10-01

Recruiting

The Multicentre Selective Lymphadenectomy Trial - 3

NCT07049276Cutaneous Melanoma, Stage III

Melanoma Institute Australia

Not applicable

1,500

Ramat Gan

2025-10-01

Active, closed

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

896

Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan

2025-10-01

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Tel Aviv

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Haifa, Tel Aviv

2025-09-28

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2025-09-17

Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

DrugEmpasiprubart

argenx

Phase 3

160

Hadera, Ramat Gan

2025-09-16

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Petah Tikva, Ramat Gan, Jerusalem, Hadera, Haifa

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-09-10

Recruiting

Azithromycin and Ampicillin for Late PPROM

NCT07183462Pregnancy Complications, Infectious, Premature Birth, Neonatal Diseases and Abnormalities, Antibiotic Prophylaxis

Sheba Medical Center

Phase 4

311

Ramat Gan

2025-09-10

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Haifa, Jerusalem, KfarSava, Petah Tikva, Ramat Gan, Tel Aviv

2025-09-04

Recruiting

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745Refractory Autoimmune Diseases

DrugsTocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

125

Ramat Gan, Jerusalem

2025-09-04

Not yet open

Microbiome and Polycystic Ovaries

NCT04836910Polycystic Ovary Syndrome, Microbial Colonization

DrugMetformin

Sheba Medical Center

Observational

Ramat Gan

2025-09-01

Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2

ADARx Pharmaceuticals, Inc.

Phase 3

Ramat Gan, Ashkelon, Tel Aviv

2025-08-28

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321Invasive Mold Infections

DrugFosmanogepix

Basilea Pharmaceutica

Phase 3

234

Haifa, Ramat Gan, Tel Aviv, Tsrifin

2025-08-26

Recruiting

Comparison of Surgical Management of Early Pregnancy Loss by Suction Curettage Versus Hysteroscopy in Patients Undergoing In-vitro Fertilization (IVF)

NCT07143578Early Abortion, Pregnancy Loss, Early

Assaf-Harofeh Medical Center

Not applicable

Be’er Ya‘aqov, Ramat Gan

2025-08-20

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Kefar Sava, Ramat Gan, Haifa, Petah Tikva, Tsrifin

2025-08-06

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2025-08-06

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

Petah Tikva, Ramat Gan, Jerusalem, Haifa, Tel Aviv

2025-08-05

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Petah Tikva, Ramat Gan, Haifa

2025-08-03

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Ashdod, Hadera, Haifa, Holon, Jerusalem, Nahariya, Ramat Gan, Safed

2025-08-01

Recruiting

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

NCT07185815Schizophrenia, Bipolar I Disorder, Major Depressive Disorder

DrugCariprazine

Mapi Pharma Ltd.

Phase 1/2

Beersheba, Ness Ziona, Ramat Gan, Tel Aviv

2025-08-01

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)

DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin

AbbVie

Phase 2

377

Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2025-07-30

Recruiting

High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients

NCT07094724West Nile Fever

DrugPlasma

Gili Regev-Yochay MD

Phase 2

Ramat Gan

2025-07-30

Recruiting

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905Hemophilia B

CSL Behring

Phase 3

Ramat Gan

2025-07-28

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2025-07-23

Recruiting

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

NCT06844214Myotonic Dystrophy

Sanofi

Phase 1/2

Ramat Gan

2025-07-23

Recruiting

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

NCT07030712Metastatic Neoplasm

Merck Sharp & Dohme LLC

Phase 1

Haifa, Ramat Gan

2025-07-23

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)

DrugsEYLEA (aflibercept)·4D-150 IVT

4D Molecular Therapeutics

Phase 3

480

Haifa, Holon, Jerusalem, Ramat Gan, Rehovot, Tel Aviv

2025-07-22

Recruiting

Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs

NCT07038785Breast Cancer

SpotitEarly

Observational

1,204

Haifa, Ramat Gan, Tel Aviv

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Beersheba, Haifa, Jerusalem, Ramat Gan

2025-07-21

Active, closed

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

NCT06888921Ovarian Cancer, Ovarian Cancer Recurrent

Compugen Ltd

Phase 1/2

Ashdod, Haifa, Holon, Jerusalem, Ramat Gan

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2025-07-20

Recruiting

Platelet Rich Plasma for Uterine Scar

NCT05224726Cesarean Section Complications, Uterine Bleeding, Pelvic Pain, Menstrual Irregularity

The University of Texas Health Science Center, Houston

Not applicable

Ramat Gan

2025-07-19

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Hod HaSharon, Ness Ziona, Petah Tikva, Ramat Gan, Beersheba, Ashkelon, Jerusalem

2025-07-18

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

NCT07011745Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Ramat Gan, Petch Tikva, Netanya, Rishon Le'Tzion

2025-07-16

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsLeucovorin/levofolinate calcium·Bevacizumab biosimilar·Calderasib·Mvasi

Merck Sharp & Dohme LLC

Phase 3

477

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-07-16

Active, closed

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Ramat Gan, Jerusalem

2025-07-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-07-03

Not yet open

vNOTES for Salpingo-oophorectomy

NCT04012710Surgery

Sheba Medical Center

Not applicable

100

Ramat Gan

2025-07-03

Active, closed

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118Prostatic Cancer, Castration-Resistant

DrugsLuxdegalutamide·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

138

Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-07-03

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

2,400

Haifa, Kfar Saba, Ramat Gan, Tsrifin

2025-06-30

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

NCT06892522Multiple Myeloma

DrugsMezigdomide·Etentamig·Iberdomide·Carfilzomib

AbbVie

Phase 1/2

602

Petah Tikva, Beersheba, Ramat Gan, Haifa, Jerusalem

2025-06-30

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Ashdod, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Ashdod, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2025-06-26

Recruiting

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT06982820Depressive Disorder, Major

GrayMatters Health Ltd.

Not applicable

170

Ramat Gan

2025-06-25

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

210

Ramat Gan, Haifa, Nahariya, Tzfat, Beersheba, Jerusalem, Kfar Saba, Petah Tikva

2025-06-19

Recruiting

Seizure Prediction Using Wearable EEG

NCT06978842Epilepsy

Dux Healthcare Inc.

Observational

150

Haifa, Ramat Gan

2025-06-19

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Petah Tikva, Tsrifin, Ashdod, Beersheba, Ramat Gan, Tel Aviv, Haifa

2025-06-17

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features

DrugKarXT

Bristol-Myers Squibb

Phase 3

274

Hod HaSharon, Ness Ziona, Petah Tikva, Ramat Gan, Beersheba, Jerusalem

2025-06-13

Recruiting

The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

NCT06854328Post-Traumatic Stress Disorder in Adolescence

GrayMatters Health Ltd.

Not applicable

Ramat Gan

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Hadera, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-06-10

Active, closed

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609Angelman Syndrome

DrugObudanersen

Ionis Pharmaceuticals, Inc.

Phase 3

156

Ramat Gan

2025-06-10

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-06-04

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

Petah Tikva, Nahariya, Beersheba, Be’er Ya‘aqov, Ramat Gan, Rehovot

2025-06-01

Active, closed

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Afula, Jerusalem, Petah Tikva, Ramat Gan

2025-05-29

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-28

Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT06941272Malignant Neoplasm

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Ramat Gan

2025-05-26

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Beersheba, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-22

Active, closed

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085Carcinoma, Non-Small-Cell Lung

DrugsR-DXd·Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 2

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-13

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2025-05-13

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Haifa, Petah Tikva, Ramat Gan

2025-05-12

Recruiting

Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide

NCT06497595Type 2 Diabetes Mellitus in Obese

Sheba Medical Center

Not applicable

Jerusalem, Ramat Gan

2025-05-11

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-06

Recruiting

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases

HepaRegeniX GmbH

Phase 1/2

Petah Tikva, Ramat Gan, Tel Aviv

2025-05-06

Recruiting

Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer

NCT06963307Lung Cancer, Non-Small Cell

JaxBio Ltd

Observational

300

Ramat Gan

2025-05

Active, closed

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

905

Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-04-25

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Haifa

2025-04-24

Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770Severe Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

288

Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2025-04-24

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-04-15

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884Lymphoma, Large B-Cell, Diffuse

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2

594

Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv

2025-04-11

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Afula, Beersheba, Hadera, Haifa, Jerusalem, Ramat Gan, Tel Aviv

2025-04-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Hadera, Haifa, Jerusalem, Kfar Saba, Ramat Gan

2025-04-09

Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907Non-small Cell Lung Cancer

DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 2

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-03-30

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Haifa, Jerusalem, Kfar Saba, Ramat Gan

2025-03-27

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Haifa, Jerusalem, Kfar Saba, Ramat Gan, Rehovot

2025-03-26

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

Haifa, Petah Tikva, Ramat Gan

2025-03-25

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

NCT06878261Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Ashkelon, Haifa, Jerusalem, Kfar Saba, Ramat Gan, Rehovot, Tel Aviv

2025-03-25

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Beersheba, Haifa, Jerusalem, Ramat Gan

2025-03-17

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Paraplatin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Beersheba, Be’er Ya‘aqov, Haifa, Herzelia, Holon, Jerusalem, Petah Tikva, Ramat Gan

2025-03-14

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290ANCA Associated Vasculitis (AAV)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

126

Haifa, Ramat Gan

2025-03-13

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin, Haifa

2025-03-13

Recruiting

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

NCT06839144Ovarian Cancer, Ovarian Cancer Metastatic Recurrent

Tel-Aviv Sourasky Medical Center

Phase 2

Ramat Gan, Tel Aviv

2025-03-12

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Ramat Gan, Jerusalem, Tel Aviv

2025-03-12

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Ashdod, Ashkelon, Haifa, Nahariya, Ramat Gan, Tel Aviv

2025-03-03

Active, closed

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988Type 1 Diabetes Mellitus

DrugBrivekimig

Sanofi

Phase 2

Jerusalem, Kefar Sava, Ramat Gan

2025-02-28

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-02-27

Recruiting

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670Prostate Cancer

DrugAAA817

Novartis Pharmaceuticals

Phase 2/3

443

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-02-27

Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394Breast Neoplasms, Breast Cancer

DrugsOgivri·Herzuma·Patritumab deruxtecan·Tucatinib

Merck Sharp & Dohme LLC

Phase 1/2

181

Haifa, Petah Tikva, Ramat Gan

2025-02-26

Recruiting

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949Sjögren's Syndrome

DrugDazodalibep

Amgen

Phase 3

844

Kafr Saba, Ramat Gan

2025-02-25

Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098Thrombocytopenia, Neonatal Alloimmune

DrugsImmunoglobulins·Nipocalimab·IVIG·Prednisone

Janssen Research & Development, LLC

Phase 3

Ramat Gan

2025-02-10

Recruiting

ARC101 in Advanced Solid Tumors

NCT06672185Advanced Solid Tumor

Third Arc Bio

Phase 1

Haifa, Ramat Gan, Tel Aviv

2025-02-05

Active, closed

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2025-02-03

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Kfar Saba, Ramat Gan, Tel Aviv, Haifa, Jerusalem, Nahariya

2025-01-31

Active, closed

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsABBV-453·Obinutuzumab

AbbVie

Phase 1

Tsrifin, Jerusalem, Ramat Gan

2025-01-27

Recruiting

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

NCT06698796Dermatomyositis, Polymyositis

Pfizer

Phase 3

211

Ramat Gan

2025-01-22

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951Urothelial Carcinoma

DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine

AbbVie

Phase 2

150

Kfar Saba, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2025-01-20

Recruiting

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939Non-Small Cell Lung Cancer, c-MET

DrugTelisotuzumab vedotin

AbbVie

Phase 2

150

Kefar Sava, Petah Tikva, Ramat Gan, Haifa, Jerusalem

2025-01-20

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)

Neuron23 Inc.

Phase 2

150

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2025-01-17

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Ashkelon, Haifa, Kfar Saba, Ramat Gan

2025-01-15

Recruiting

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

NCT06759649Neoplasm, Cancer, Malignant Tumors

DrugZimberelimab

Compugen Ltd

Phase 1

200

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-01-07

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib

Pfizer

Phase 3

1,035

Petah Tikva, Ramat Gan, Jerusalem, Haifa, Tel Aviv

2025-01-06

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Afula, Jerusalem, Petah Tikva, Ramat Gan

2024-12-24

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Haifa, Ramat Gan, Tel Aviv

2024-12-17

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Beersheba, Haifa, Kfar Saba, Ramat Gan

2024-12-16

Recruiting

Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)

NCT06748651Temporomandibular Joint Osteoarthritis

DrugAllocetra

Dr. Amit Druyan

Phase 1

Ramat Gan

2024-12-15

Active, closed

Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults

NCT06547151Hypoparathyroidism

Amorphical Ltd.

Phase 2

Ashdod, Haifa, Jerusalem, Petah Tikva, Ashkelon, Beersheba, Ramat Gan, Rehovot

2024-12-15

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-12-12

Active, closed

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

350

Beersheba, Ramat Gan

2024-12-11

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Haifa, Holon, Ramat Gan, Tel Aviv, Tsrifin

2024-12-11

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Jerusalem, Ramat Gan

2024-12-09

Recruiting

Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals

NCT06762730HIV Infected Individuals, Osteopenia

DrugZoledronic Acid

Hadassah Medical Organization

Phase 4

110

Haifa, Jerusalem, Ramat Gan

2024-12-09

Recruiting

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis

DrugsRamantamig·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 1

276

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-12-04

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Ashkelon, Haifa, Har Poriyya, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-12-04

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Beer Yaacov, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-11-18

Recruiting

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

150

Beer Jacob, Jerusalem, Ramat Gan

2024-11-18

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-11-14

Recruiting

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06449651Thrombocytopenia, Neonatal Alloimmune

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

Ramat Gan

2024-11-11

Active, closed

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192Metastatic Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

Petah Tikva, Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-11-08

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Haifa, Ramat Gan, Tel Aviv

2024-10-29

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

Petah Tikva, Ramat Gan, Tel Aviv

2024-10-24

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Platinol-AQ·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

680

Haifa, Jerusalem, Kfar Saba, Ramat Gan

2024-10-21

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-10-18

Recruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer

Fundacio Clinic Barcelona

Not applicable

304

Ramat Gan

2024-10-11

Active, closed

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

768

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2024-10-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Petah Tikva, Ramat Gan, Haifa, Afula, Nahariya, Jerusalem, Tel Aviv

2024-10-04

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

Jerusalem, Ramat Gan, Tel Aviv

2024-09-30

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Jerusalem, Ashkelon, Petah Tikva, Ramat Gan

2024-09-26

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Genmab

Phase 3

699

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Be’er Ya‘aqov, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-09-24

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Petah Tikva, Ramat Gan

2024-09-04

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Haifa, Ramat Gan, Tel Aviv

2024-09-04

Recruiting

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

NCT05922124Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia

DrugsAmpicillin-sulbactam·Cefiderocol·Colistin·Meropenem

Rambam Health Care Campus

Phase 4

734

Haifa, Ramat Gan, Tel Aviv

2024-09-01

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Hadera, Haifa, Holon, Jerusalem, Ramat Gan, Tel Aviv

2024-08-28

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Petah Tikva, Afula, Jerusalem, Beersheba, Ramat Gan

2024-08-19

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Ramat Gan

2024-08-16

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Sakhnin, Tsrifin

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-08-01

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Haifa, Holon, Jerusalem, Ramat Gan

2024-07-24

Active, closed

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Petah Tikva, Ramat Gan

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2024-07-16

Recruiting

Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection

NCT07131163Stage II-III Non-small Cell Lung Cancer

Sheba Medical Center

Observational

Ramat Gan

2024-07-16

Recruiting

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

NCT07777744Ventricular Tachycardia (VT), Premature Ventricular Complexes

University Hospital, Basel, Switzerland

Observational

15,000

Ramat Gan

2024-07-01

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Petah Tikva, Afula, Nahariya, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2024-06-27

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Genmab

Phase 3

621

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-06-24

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Afula, Haifa, Jerusalem, Kfar Saba, Ramat Gan

2024-06-20

Active, closed

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516Multiple Myeloma

DrugEtentamig

AbbVie

Phase 1

Jerusalem, Ramat Gan, Tel Aviv

2024-06-17

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-06-10

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-06-07

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-06-06

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2024-06-05

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2024-06-03

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Haifa, Ramat Gan

2024-05-21

Active, closed

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Haifa, Petah Tikva, Ramat Gan

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv

2024-05-19

Recruiting

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

NCT05919238Locally Advanced Unresectable Pancreatic Adenocarcinoma

Impact Biotech Ltd

Phase 1

Ramat Gan

2024-05-15

Active, closed

The OPBC-07/microNAC Study

NCT06529302Breast Cancer

University Hospital, Basel, Switzerland

Observational

2,000

Ramat Gan

2024-05-15

Recruiting

Collection of Blood and Skin Samples From Patients With Primary Mitochondrial Diseases and Healthy Volunteers

NCT06474104Primary Mitochondrial Diseases

Minovia Therapeutics Ltd.

Observational

100

Ramat Gan

2024-05-12

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot

2024-04-30

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Afula, Ashkelon, Haifa, Holon, Nahariya, Petah Tikva, Ramat Gan, Rehovot

2024-04-27

Recruiting

A Platform Trial for Gram Negative Bloodstream Infections

NCT06537609Gram-negative Bacteremia

Sunnybrook Health Sciences Centre

Not applicable

2,500

Ramat Gan

2024-04-24

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Haifa, Ramat Gan, Sderot, Tel Aviv, Yeruham

2024-04-18

Active, closed

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935Crohn's Disease

DrugsTremfya·Guselkumab

Janssen-Cilag Ltd.

Phase 3

120

Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-04-17

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-04-14

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-04-03

Active, closed

Clemastine Treatment in Individuals With Williams Syndrome

NCT06087757Williams Syndrome

Sheba Medical Center

Phase 2

Ramat Gan, Tel Aviv

2024-04-01

Active, closed

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950Ulcerative Colitis

DrugZasocitinib

Takeda

Phase 2

213

Ashdod, Beersheba, Jerusalem, Ramat Gan

2024-03-29

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Ashkelon, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2024-03-29

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Tsrifin, Jerusalem, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva

2024-03-23

Active, closed

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

NCT06297603Type 2 Diabetes

DrugRetatrutide

Eli Lilly and Company

Phase 3

320

Atlit, Beersheba, Herzliya, Holon, Jerusalem, Ramat Gan, Sakhnin

2024-03-15

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-03-13

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

Ramat Gan, Haifa, Jerusalem

2024-03-08

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-03-07

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461Crohn's Disease

DrugZasocitinib

Takeda

Phase 2

268

Ashdod, Beersheba, Jerusalem, Kfar Saba, Ramat Gan

2024-03-05

Recruiting

Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults

NCT07596576Healthy Aging, Healthspan, Biological Age, Intrinsic Capacity

Sheba Medical Center

Not applicable

1,500

Ramat Gan

2024-03-01

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Beersheba, Ramat Gan, Tel Aviv

2024-02-29

Active, closed

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

DrugsLeuprolide·Goserelin·Exemestane·Ribociclib

Novartis Pharmaceuticals

Phase 3

1,466

Beersheba, Petah Tikva, Ramat Gan, Tel Aviv

2024-02-28

Active, closed

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159Myasthenia Gravis, Generalized

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Haifa, Ramat Gan, Safed

2024-02-23

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

463

Haifa, Ramat Gan, Rehovot, Tel Aviv

2024-02-21

Recruiting

Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

NCT06206850Non-squamous NSCLC

DrugsTagrisso·Osimertinib

Jair Bar, M.D., Ph.D.

Phase 2

Ramat Gan

2024-02-19

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv

2024-02-08

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Kfar Saba, Petah Tikva, Afula, Jerusalem, Beersheba, Ramat Gan, Tel Aviv

2024-02-05

Recruiting

COMMETS- Combination MCI Metabolic Syndrome

NCT06072963Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome

DrugSemaglutide

Rutgers, The State University of New Jersey

Phase 2

Ramat Gan

2024-01-30

Active, closed

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426Parkinson's Disease (PD)

AbbVie

Observational

427

Jerusalem, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-01-23

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

Petah Tikva, Ramat Gan, Tel Aviv

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Be’er Ya‘aqov, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2024-01-22

Recruiting

Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

NCT06907498Dientamoeba Fragilis Infection

Sheba Medical Center

Not applicable

Ramat Gan

2024-01-22

Recruiting

A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

NCT05641844Anal Fistula

RedDress Ltd.

Not applicable

110

Ramat Gan

2024-01-20

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Ashdod, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2024-01-18

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Ashkelon, Ramat Gan

2024-01-03

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2023-12-31

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2023-12-31

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Ashdod, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-28

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157Neoplasms

DrugsMomelotinib·Ruxolitinib

Janssen Research & Development, LLC

Phase 1

300

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-12-20

Recruiting

Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction

NCT05992363Hydronephrosis; Obstruction, Ureter, Renal Failure, Malignancy, Ureter Obstruction

Rabin Medical Center

Not applicable

106

Petah Tikva, Ramat Gan

2023-12-20

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517Hemolytic Disease of the Fetus and Newborn

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

120

Jerusalem, Petah Tikva, Ramat Gan

2023-12-20

Recruiting

Observational Study Protocol: LIVER-R

NCT06252753Hepatobiliary Cancers

AstraZeneca

Observational

4,000

Nahariya, Ramat Gan, Jerusalem, Tel Aviv

2023-12-20

Recruiting

Danon Disease Natural History Study

NCT06214507Danon Disease

Rocket Pharmaceuticals Inc.

Observational

Ramat Gan

2023-12-20

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv, Haifa

2023-12-19

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Jerusalem, Ramat Gan, Tel Aviv

2023-12-18

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-18

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Haifa, Ramat Gan, Safed

2023-12-13

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tsrifin

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Ashdod, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-12

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-11

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-12-07

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-06

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Petah Tikva, Ramat Gan, Haifa, Afula, Nahariya, Nazareth, Jerusalem, Tel Aviv

2023-12-01

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

289

Jerusalem, Ramat Gan, Haifa

2023-11-15

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Petah Tikva, Ramat Gan

2023-11-14

Recruiting

Does Sexual Intercourse Affect the Outcomes of Frozen-thawed Embryo Transfer?

NCT06134609Embryo Transfer, Fertilization in Vitro, Coitus

Sheba Medical Center

Not applicable

656

Ramat Gan

2023-11-13

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2023-11-13

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413Unresectable Metastatic Colorectal Cancer

DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie

Phase 2

280

Kfar Saba, Jerusalem, Ramat Gan, Tel Aviv, Haifa

2023-11-12

Active, closed

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571NASH/MASH, NAFLD/MASLD

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

700

Petah Tikva, Ramat Gan, Haifa, Afula, Nahariya, Nazareth, Jerusalem, Tel Aviv

2023-11-10

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma

DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab

AbbVie

Phase 1

325

Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2023-11-09

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Afula, Haifa, Jerusalem, Kfar Saba, Ramat Gan

2023-11-08

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot

2023-11-07

Active, closed

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Janssen Research & Development, LLC

Phase 1

Jerusalem, Ramat Gan

2023-11-06

Not yet open

Hepatopulmonary Radio-sterilization With Immunotherapy

NCT06053996Colon Cancer, Liver Metastasis Colon Cancer, Rectal Cancer

Sheba Medical Center

Not applicable

Ramat Gan

2023-11-01

Active, closed

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT05987332Metastatic Uveal Melanoma

DrugsDarovasertib·Crizotinib·Dacarbazine·Yervoy

IDEAYA Biosciences

Phase 2/3

420

Jerusalem, Ramat Gan

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Kfar Saba, Ramat Gan

2023-10-27

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2023-10-25

Active, closed

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06075667Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

160

Beer Yaacov, Petah Tikva, Ramat Gan, Jerusalem, Afula, Haifa, Beersheba

2023-10-16

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Petah Tikva, Ramat Gan, Beersheba, Tel Aviv, Haifa, Jerusalem

2023-10-16

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv, Haifa

2023-10-11

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Jerusalem, Ramat Gan, Tel Aviv

2023-10-10

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Afula, Haifa, Jerusalem, Kfar Saba, Nahariya, Ramat Gan

2023-10-05

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Jerusalem, Ramat Gan, Beersheba, Hafia, Kefar Sava, Petah Tikva, Tel Aviv

2023-09-22

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-09-18

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Haifa, Holon, Kfar Saba, Ramat Gan, Tel Aviv, Tiberias

2023-09-13

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Ramat Gan, Kfar Saba

2023-09-11

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-09-07

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

Jerusalem, Ramat Gan

2023-09-01

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Ashkelon, Jerusalem, Kfar Saba, Ramat Gan, Safed

2023-08-31

Recruiting

CPAP for Esophageal Cancer With Radiotherapy

NCT06037902Esophageal Cancer

Sheba Medical Center

Not applicable

Ramat Gan

2023-08-21

By invitation

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

NCT06846736Alk-positive Non-Small Cell Lung Cancer, ALK-inhibitor Treated

Sheba Medical Center

Observational

200

Ramat Gan

2023-08-13

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT05927571Relapsed or Refractory Multiple Myeloma

DrugsCevostamab·Elranatamab·Tocilizumab

Genentech, Inc.

Phase 1

120

Ramat Gan, Haifa, Jerusalem, Tel Aviv

2023-08-10

Active, closed

Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.

NCT05196269Breast Cancer

Fundacao Champalimaud

Not applicable

1,030

Ramat Gan

2023-08-08

Active, closed

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Pemetrexed

Regeneron Pharmaceuticals

Phase 2/3

160

Ramat Gan, Tel Aviv

2023-08-08

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic

DrugsNemtabrutinib·Venetoclax·Rituximab

Merck Sharp & Dohme LLC

Phase 3

735

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-08-08

Recruiting

A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease

NCT06221254Crohn Disease

Soroka University Medical Center

Not applicable

200

Beersheba, Haifa, Petah Tikva, Ramat Gan

2023-08-01

Recruiting

Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

NCT06017869Mitochondrial Diseases, Pearson Syndrome

Minovia Therapeutics Ltd.

Phase 2

Ramat Gan

2023-07-31

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Kfar Saba, Jerusalem, Nahariya, Ramat Gan, Tel Aviv, Haifa

2023-07-25

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Afula, Jerusalem, Petah Tikva, Ramat Gan

2023-07-19

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Jerusalem, Ashkelon, Petah Tikva, Ramat Gan

2023-07-11

Recruiting

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

NCT05909618Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma

DrugsCrizanlizumab·Opdivo·Nivolumab

Sheba Medical Center

Phase 2

Ramat Gan

2023-07-11

Active, closed

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy

DrugZigakibart

Novartis Pharmaceuticals

Phase 3

383

Beersheba, Holon, Ramat Gan, Be’er Ya‘aqov, Tel Aviv

2023-07-06

Active, closed

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-07-06

Active, closed

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms

DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

390

Haifa, Petah Tikva, Ramat Gan

2023-06-23

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Ashdod, Beer Ya'Aqov, Hadera, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2023-06-22

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Petah Tikva, Safed, Ramat Gan, Tel Aviv, Haifa

2023-06-21

Recruiting

Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma

NCT07636252Lung Adenocarcinoma, Malignant Pleural Effusions (Mpe)

Sheba Medical Center

Observational

400

Ramat Gan

2023-06-14

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone

GlaxoSmithKline

Phase 1/2

123

Beersheba, Jerusalem, Ramat Gan

2023-06-14

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Jerusalem, Ramat Gan, Tel Aviv, Petah Tikva

2023-06-09

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

AbbVie

Phase 1

135

Tsrifin, Jerusalem, Ramat Gan, Tel Aviv

2023-06-09

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Haifa, Ramat Gan

2023-06-05

By invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949Migraine Prophylaxis

DrugAtogepant

AbbVie

Phase 3

650

Beer Ya'akov, Hadera, Haifa, Ramat Gan, Tel Aviv

2023-06-05

Recruiting

Closed-loop Medtronic 780G System in Youth With Type 1 Diabetes

NCT05908708Type 1 Diabetes, Child, Only

Sheba Medical Center

Observational

120

Ramat Gan

2023-06-01

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Petah Tikva, Ramat Gan, Tel Aviv

2023-05-20

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Petah Tikva, Ramat Gan, Haifa, Tel Aviv

2023-05-17

Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100Focal Onset Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

360

Jerusalem, Ramat Gan, Rehovot, Tel Aviv

2023-05-09

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-05-08

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation

Omeros Corporation

Phase 2

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-05-01

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394Episodic Migraine

DrugAtogepant

AbbVie

Phase 3

450

Beer Ya'akov, Hadera, Ramat Gan, Tel Aviv, Haifa

2023-05-01

Active, closed

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

DrugABBV-319

AbbVie

Phase 1

Ramat Gan, Jerusalem

2023-04-26

Active, closed

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931Endometrial Cancer

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 3

257

Hadera, Holon, Jerusalem, Ramat Gan

2023-04-18

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

Beer Ya'akov, Petah Tikva, Jerusalem, Ramat Gan

2023-04-04

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Afula, Ashdod, Haifa, Jerusalem, Kfar Saba, Nahariya, Ramat Gan, Rehovot

2023-03-31

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Jerusalem, Ramat Gan, Tel Aviv

2023-03-30

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Hadera, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2023-03-29

Active, closed

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

NCT05622708Non-radiographic Axial Spondyloarthritis

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

240

Kfar Saba, Ramat Gan, Tel Aviv

2023-03-28

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632Multiple Myeloma

DrugEtentamig

AbbVie

Phase 1

250

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv

2023-03-21

Active, closed

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

NCT05766501HIV Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

641

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-03-17

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Holon, Kfar Saba, Petah Tikva, Rehovot, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2023-03-15

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Holon, Beersheba, Haifa, Jerusalem, Nahariya, Poria – Neve Oved, Ramat Gan, Rehovot

2023-03-09

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-03-08

Active, closed

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

436

Haifa, Ramat Gan

2023-03-02

Recruiting

Oral Health, Saliva Viscosity and Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)

NCT07118280Oculopharyngeal Muscular Dystrophy

Sheba Medical Center

Observational

100

Ramat Gan

2023-03-01

Active, closed

A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.

NCT05637112Systemic Lupus Erythematosus

AstraZeneca

Observational

551

Kfar Saba, Tel Hashomer, Tiberias, Haifa, Jerusalem, Afula, Ramat Gan, Tel Aviv

2023-02-27

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Petah Tikva, Ramat Gan

2023-02-27

Active, closed

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

NCT05630755HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

514

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2023-02-17

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Beersheba, Haifa, Jerusalem, Naharya, Petah Tikva, Ramat Gan, Safed, Tel Aviv

2023-02-15

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Jerusalem, Ramat Gan, Rehovot, Tel Aviv

2023-02-14

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

195

Jerusalem, Ramat Gan

2023-02-10

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Kfar Saba, Tel Aviv, Haifa, Jerusalem, Ramat Gan, Petah Tikva

2023-02-08

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2023-01-30

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2023-01-24

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Ramat Gan, Beersheba, Haifa, Jerusalem, Petah Tikva, Petah Tikvah, Tel Aviv

2023-01-23

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Petah Tikva, Ramat Gan

2023-01-19

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2023-01-16

Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis

DrugDapansutrile

Olatec Therapeutics, Inc.

Phase 2/3

300

Afula, Haifa, Petah Tikva, Ramat Gan

2023-01-06

By invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

NCT05768386Hemophilia A

BioMarin Pharmaceutical

Observational

172

Ramat Gan

2023-01-01

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2022-12-13

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Afula, Ashkelon, Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan

2022-12-13

Recruiting

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

NCT05611801Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

100

Ramat Gan

2022-12-09

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Ramat Gan, Haifa, Jerusalem

2022-12-05

Active, closed

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer

DrugPF-07799933

Pfizer

Phase 1

148

Petah Tikva, Ramat Gan, Jerusalem, Beersheba

2022-11-30

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

NCT05584670Solid Tumor

DrugsSAR445877·ADG126·Zirabev·Erbitux

Sanofi

Phase 1/2

542

Jerusalem, Ramat Gan, Tel Aviv, Tzrifin

2022-11-29

Active, closed

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830Urothelial Carcinoma

DrugsMK-3120·Zilovertamab vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Petah Tikva, Ramat Gan

2022-11-16

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsLMWH·Direct Anticoagulant·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2022-11-11

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv

2022-11-10

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515Non-Hodgkin Lymphoma

DrugsGolcadomide·Iberdomide·Mosunetuzumab·Glofitamab

Hoffmann-La Roche

Phase 1

121

Beersheba, Haifa, Jerusalem, Ramat Gan, Tel Aviv

2022-10-26

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-10-25

Active, closed

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

Jerusalem, Ramat Gan, Tel Aviv

2022-10-17

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Ashdod, Jerusalem, Kfar Saba, Nahariya, Ramat Gan, Tel Aviv

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Afula, Be’er Ya‘aqov, Hadera, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan

2022-10-13

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan

2022-10-11

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2022-10-04

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Petah Tikva, Haifa, Ramat Gan

2022-10-04

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-10-04

Active, closed

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma

NCT05323253Recurrent Squamous Cell Carcinoma

Alpha Tau Medical LTD.

Not applicable

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2022-09-21

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Kfar Saba, Ramat Gan, Jerusalem, Haifa, Tel Aviv, Peatch Tikva

2022-09-20

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Tsrifin, Jerusalem, Safed, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2022-09-20

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

381

Ramat Gan

2022-09-16

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Afula, Haifa, Holon, Jerusalem, Nahariya, Ramat Gan

2022-09-13

Active, closed

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-09-08

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Rehovot, Hadera, Jerusalem, Ashkelon, Ramat Gan, Haifa, Kfar Saba, Petah Tikva

2022-09-06

Active, closed

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

NCT05378425Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer

DrugsKeytruda·Pembrolizumab

Nectin Therapeutics Ltd

Phase 1

Jerusalem, Ramat Gan

2022-09-01

Recruiting

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

NCT05156983Coagulation Disorder

Takeda

Phase 3

440

Beer Yaacov, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-08-24

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2022-08-24

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Afula, Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-08-22

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Ramat Gan, Haifa, Jerusalem

2022-08-17

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Yeruham

2022-08-05

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Kfar Saba, Ramat Gan

2022-08-04

Active, closed

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

NCT05433584Type 2 Diabetes

DrugTirzepatide

Eli Lilly and Company

Phase 4

780

Holon, Petah Tikva, Ramat Gan, Rehovot, Jerusalem, Haifa, Sakhnin, Atlit

2022-08-01

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsNemtabrutinib·Zilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 2

189

Afula, Beersheba, Haifa, Jerusalem, Nahariya, Ramat Gan

2022-07-21

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

NCT05406401Lymphoma, Large B-Cell, Diffuse (DLBCL)

DrugsRituximab Biosimilar·Zilovertamab vedotin·Truxima·Adriamycin

Merck Sharp & Dohme LLC

Phase 2

Jerusalem, Ramat Gan

2022-07-14

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Ramat Gan

2022-07-14

Active, closed

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

NCT05142696Extensive Stage Small Cell Lung Cancer

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera·Atezolizumab

Novartis Pharmaceuticals

Phase 1/2

Beersheba, Ramat Gan, Tel Aviv

2022-07-13

Active, closed

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma

DrugsPF-07799933·Binimetinib·Erbitux·Midazolam

Pfizer

Phase 1

103

Tel Aviv, Jerusalem, Ramat Gan, Haifa

2022-07-05

Recruiting

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173Congenital Antithrombin Deficiency

Octapharma

Phase 3

Petah Tikva, Ramat Gan

2022-07-01

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv

2022-06-14

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Haifa, Kfar Saba, Ramat Gan, Tel Aviv

2022-06-10

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Petah Tikva, Ramat Gan, Tel Aviv

2022-05-23

Active, closed

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

NCT05308654Relapsed/Refractory Multiple Myeloma

DrugsABBV-453·Daratumumab·Lenalidomide·Dexamethasone

AbbVie

Phase 1

Jerusalem, Ramat Gan, Tel Aviv

2022-05-17

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-05-03

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2022-05-03

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617Seizures, Lennox Gastaut Syndrome

SK Life Science, Inc.

Phase 3

252

Tel Aviv, Beersheba, Jerusalem, Ramat Gan

2022-04-28

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Haifa, Tel Aviv

2022-04-14

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Haifa, Kfar Saba, Nahariya, Petach Tikvah, Ramat Gan, Tel Aviv

2022-03-29

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436Chronic Lymphocytic Leukemia (CLL)

DrugsVenclexta·Obinutuzumab·Venetoclax

AbbVie

Phase 2

Jerusalem, Ramat Gan, Tel Aviv, Petah Tikva

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Petah Tikva, Ramat Gan, Jerusalem, Haifa, Beersheba, Tel Aviv

2022-03-25

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Platinol-AQ·Tecentriq·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

460

Haifa, Jerusalem, Ramat Gan

2022-03-24

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-03-15

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

Kfar Saba, Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv

2022-03-11

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Ashdod, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-03-10

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Petah Tikva, Ramat Gan, Tel Aviv

2022-03-08

Recruiting

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

NCT04665037Invasive Fungal Infection

DrugPosaconazole

Merck Sharp & Dohme LLC

Phase 2

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2022-02-22

Recruiting

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119Staphylococcus Aureus Bacteremia

DrugsDaptomycin·Benzylpenicillin·Clindamycin·Cefazolin

University of Melbourne

Phase 4

8,000

Haifa, Petah Tikva, Ramat Gan

2022-02-16

Active, closed

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

NCT04573023Mucopolysaccharidosis II

DrugsIdursulfase·JR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Afula, Ramat Gan

2022-02-14

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Platinol-AQ·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

280

Beersheba, Haifa, Holon, Jerusalem, Ramat Gan

2022-02-03

Recruiting

Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry

NCT07146256Oculopharyngeal Muscular Dystrophy (OPMD)

Sheba Medical Center

Observational

300

Ramat Gan

2022-02-01

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Afula, Beersheba, Ramat Gan, Rehovot, Tzrifin

2022-01-19

Active, closed

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

NCT05127226Angelman Syndrome

DrugObudanersen

Ionis Pharmaceuticals, Inc.

Phase 1/2

Ramat Gan

2021-12-22

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Ramat Gan, Jerusalem, Haifa

2021-12-20

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Haifa, Jerusalem, Kfar Saba, Ramat Gan

2021-12-17

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Keytruda

Merck Sharp & Dohme LLC

Phase 3

643

Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-12-13

Active, closed

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

NCT05000710Metastatic or Locally Advanced NSCLC

DrugsTremelimumab·Durvalumab

Sheba Medical Center

Phase 2

Ramat Gan

2021-12-09

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Ashdod, Holon, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Sefad, Tsrifin

2021-11-23

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2021-11-17

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

245

Ramat Gan

2021-11-17

Recruiting

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

NCT05047094Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma

DrugsKeytruda·Pembrolizumab

Alpha Tau Medical LTD.

Not applicable

Jerusalem, Ramat Gan, Tel Aviv

2021-11-02

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer

DrugsBudigalimab·Telisotuzumab Adizutecan·Bevacizumab

AbbVie

Phase 1

694

Beer Ya'akov, Kefar Sava, Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2021-11-01

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

Ramat Gan, Jerusalem

2021-10-27

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Petah Tikva, Ramat Gan

2021-10-25

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

Haifa, Petah Tikva, Ramat Gan

2021-10-22

Active, closed

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor

DrugsCAM2029·Octreotide LAR

Camurus AB

Phase 3

332

Haifa, Jerusalem, Ramat Gan

2021-10-22

Active, closed

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic

DrugUstekinumab

Janssen Research & Development, LLC

Phase 3

159

Beer Yaakov, Jerusalem, Ramat Gan

2021-10-18

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Kfar Saba, Jerusalem, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2021-10-13

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Petah Tikva, Ramat Gan, Tel Aviv

2021-10-06

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Hadera, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2021-09-22

Recruiting

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

NCT05243212Multiple Myeloma, Relapse Multiple Myeloma

Sheba Medical Center

Phase 1/2

Ramat Gan

2021-09-19

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Haifa, Holon, Kfar Saba, Ramat Gan

2021-08-30

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Beer Jacob, Beersheba, Ramat Gan, Tel Aviv

2021-08-27

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Tel Aviv, Haifa, Jerusalem, Nahariya, Beersheba, Ramat Gan

2021-08-19

Active, closed

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817Small Cell Lung Carcinoma

DrugsMK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab·R-DXd

Merck Sharp & Dohme LLC

Phase 1/2

110

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2021-08-19

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Jerusalem, Ramat Gan, Tel Aviv

2021-08-19

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2021-08-18

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Ramat Gan, Tel Aviv

2021-08-12

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

562

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2021-07-16

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib

AstraZeneca

Phase 3

315

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2021-06-30

Active, closed

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248Primary Membranous Nephropathy

DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone

Hoffmann-La Roche

Phase 3

142

Ramat Gan

2021-06-25

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

DrugsSamuraciclib·Ipatasertib·Phesgo·Giredestrant

Hoffmann-La Roche

Phase 1/2

316

Jerusalem, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2021-06-22

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Ashdod, Beersheba, Haifa, Ramat Gan, Tel Aviv

2021-06-18

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

Ashkelon, Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2021-06-17

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Nivolumab·Docetaxel

Bristol-Myers Squibb

Phase 1/2

1,109

Petah Tikva, Ramat Gan, Haifa, Tel Aviv

2021-05-27

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Be'er-Sheva Southern, Petah Tikva, Ramat Gan

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2021-05-19

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2021-05-12

Active, closed

A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

NCT04903288AADC Deficiency

PTC Therapeutics

Phase 2

Ramat Gan

2021-05-12

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-05-11

Active, closed

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

NCT04764188NSCLC

DrugAlectinib

Hoffmann-La Roche

Observational

800

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2021-05-10

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

Ashkelon, Jerusalem, Kfar Saba, Ramat Gan, Safed

2021-05-06

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-04-26

Active, closed

Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

NCT04780516Psoriasis

AbbVie

Observational

141

Rehovot, Afula, Jerusalem, Safed, Ashkelon, Beersheba, Ramat Gan, Tel Aviv

2021-04-26

Recruiting

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485Low-grade Glioma, Advanced Solid Tumor

DrugTovorafenib

Day One Biopharmaceuticals, Inc.

Phase 2

141

Haifa, Petah Tikva, Ramat Gan

2021-04-22

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Platinol-AQ·Keytruda·Gemcitabine

Merck Sharp & Dohme LLC

Phase 3

808

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2021-04-21

Recruiting

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

NCT04519151Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoplasm of Stomach, Ovarian Diseases

DrugsLenvatinib·Keytruda·Pembrolizumab

Sheba Medical Center

Phase 2

Ramat Gan

2021-04-12

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Haifa, Jerusalem, Ramat Gan, Tel Aviv

2021-04-08

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-israel/city/ramat-gan

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,426 studies in total at the last sync on 12 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 648 of those studies with a site in Ramat Gan.

How many clinical trials are recruiting in Ramat Gan?

327 of the 648 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:18 UTC sync. A further 8 have not yet opened recruitment, 306 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ramat Gan), 648 studies
Phase	Studies	Recruiting	Share
Phase 3	328	133	50.6%
Phase 2	90	48	13.9%
Observational	57	38	8.8%
Phase 1/2	54	34	8.3%
Phase 1	48	24	7.4%
Not applicable	33	25	5.1%
Phase 2/3	27	18	4.2%
Phase 4	11	7	1.7%

Most active sponsors

Lead sponsors with the most studies (Ramat Gan)
Lead sponsor	Studies	Recruiting
Merck Sharp & Dohme LLC	86	50
AbbVie	67	22
Janssen Research & Development, LLC	50	22
AstraZeneca	43	15
Sheba Medical Center	30	21
Eli Lilly and Company	29	13
Novartis Pharmaceuticals	27	9
Pfizer	23	18
Hoffmann-La Roche	22	7
Sanofi	16	8

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.